NOTE: FOR RITUXIMAB, THE USE OF A BIOSIMILAR OR THE REFERENCE PRODUCT IS ON PATHWAY
| Evolent Pathways | Febrile Neutropenic Risk | Emetogenic Risk | References | |
|---|---|---|---|---|
Primary or Initial Therapy |
R-CVP (rituximab, cyclophosphamide, vincristine, prednisone)
|
Low | Moderate |
|
R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) |
Intermediate | High |
|
|
bendamustine and rituximab (BR) |
Intermediate | Moderate |
|
|
rituximab |
Low | Low |
|
|
Maintenance (Consolidation or extended dosing) |
rituximab *maintenance up to 2 years* |
Low | Low |
|
Subsequent Therapy |
rituximab |
Low | Low |
|
R-CVP (cyclophosphamide, vincristine, prednisone)
|
Low | Moderate |
|
|
R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) |
Intermediate | High |
|
|
bendamustine and rituximab (BR) |
Intermediate | Moderate |
|
|
Best Supportive Care or Clinical Trial |
Not Applicable | Not applicable |
|
Primary or Initial Therapy
R-CVP (rituximab, cyclophosphamide, vincristine, prednisone)
R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone)
bendamustine and rituximab (BR)
rituximab
Maintenance (Consolidation or extended dosing)
rituximab *maintenance up to 2 years*
Subsequent Therapy
rituximab
R-CVP (cyclophosphamide, vincristine, prednisone)
R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone)
bendamustine and rituximab (BR)
Best Supportive Care or Clinical Trial
| Regimen | Alternative | References | |||
|---|---|---|---|---|---|
| LOW VALUE REGIMENS (NON-PATHWAY) WITH SUPERIOR ALTERNATIVES | |||||
Initial therapy |
** lenalidomide and rituximab ** applies to marginal zone lymphoma |
Alternative: (CVP + R) cyclophosphamide + vincristine + prednisone + rituximab |
|||
Initial therapy
** lenalidomide and rituximab ** applies to marginal zone lymphoma